Web of Science: 40 citas, Scopus: 43 citas, Google Scholar: citas,
Delivery is key: lessons learnt from developing splice-switching antisense therapies
Godfrey, Caroline (University of Oxford. Department of Physiology, Anatomy and Genetics)
Desviat, Lourdes R (Centro de Biología Molecular Severo Ochoa UAM-CSIC)
Smedsrød, Bård (University of TromsØ. Department of Medical Biology)
Piétri-Rouxel, France (Institut de Myologie, Paris)
Denti, Michela A (Università di Trento. Centre for Integrative Biology)
Disterer, Petra (University College London. Centre for Amyloidosis and Acute Phase Proteins)
Lorain, Stéphanie (Institut de Myologie, Paris)
Nogales Gadea, Gisela (Institut Germans Trias i Pujol. Grup d'Investigació en Malalties Neuromuscular i Neuropediàtriques)
Sardone, Valentina (University College London)
Anwar, Rayan (Drug Discovery Informatics Lap, Qasemi-Research Center, Al-Qasemi Academic College)
EL Andaloussi, Samir (Karolinska Institute. Department of Laboratory Medicine)
Lehto, Taavi (University of Tartu. Institute of Technology)
Khoo, Bernard (University College London. Centre for Neuroendocrinology)
Brolin, Camilla (University of Copenhagen. Department of Cellular and Molecular Medicine)
van Roon-Mom, Willeke MC (Leiden University Medical Center. DEpartment of Human Genetics)
Goyenvalle, Aurélie (Université Versailles Saint Quentin)
Aartsma-Rus, Annemieke (Leiden University Medical Center. Department of Human Genetics)
Arechavala-Gomeza, Virginia (Neuromuscular Disorders Group. BioCruces Health Research Insitute, Bizkaia)
Universitat Autònoma de Barcelona

Fecha: 2017
Resumen: The use of splice-switching antisense therapy is highly promising, with a wealth of pre-clinical data and numerous clinical trials ongoing. Nevertheless, its potential to treat a variety of disorders has yet to be realized. The main obstacle impeding the clinical translation of this approach is the relatively poor delivery of antisense oligonucleotides to target tissues after systemic delivery. We are a group of researchers closely involved in the development of these therapies and would like to communicate our discussions concerning the validity of standard methodologies currently used in their pre-clinical development, the gaps in current knowledge and the pertinent challenges facing the field. We therefore make recommendations in order to focus future research efforts and facilitate a wider application of therapeutic antisense oligonucleotides.
Derechos: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Lengua: Anglès.
Documento: article ; article de revisió ; publishedVersion
Materia: Antisense oligonucleotides ; Delivery ; Pre-clinical models ; RNA therapy ; Toxicity
Publicado en: EMBO Molecular Medicine, Vol. 9 Núm. 5 (2017) , p. 545-557, ISSN 1757-4684

DOI: 10.15252/emmm.201607199
PMID: 28289078

13 p, 1.6 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Artículos > Artículos publicados

 Registro creado el 2018-10-10, última modificación el 2020-06-27

   Favorit i Compartir